Research Reports on Biotech Equities Celgene Sarepta Therapeutics Threshold...
NEW YORK October 6 2016 PRNewswire Today StockCallers.com has its attention directed to the Biotechnology arena which entered about a month ago in the triple leveraged ETF&160;at about $38 a share...
View ArticleBRIEFRedhill Biopharma provides progress update on RHB104 Phase III crohn's...
Redhill Biopharma provides progress update on RHB104 PhaseIII crohn's disease program and introduces option for early stopfor success in Q22017
View ArticleTillotts Pharma AG's Parent Company Zeria Pharmaceutical Receives Approval...
RHEINFELDEN Switzerland October 6 2016 PRNewswire Zeria Pharmaceutical Co. Ltd. has received the approval for a new drug application for Zentacort 3mg capsules from the Ministry of Health Labour and...
View ArticleRedHill Biopharma Ltd. RedHill Biopharma Provides Progress Update on RHB104...
An option for early stop for success for overwhelming efficacy has been introduced into the ongoing first Phase III study with RHB104 for Crohn's disease the "MAP US" study and analysis is ex...
View ArticleRedHill Biopharma Ltd. RedHill Biopharma Provides Progress Update on RHB104...
RedHill Biopharma Provides Progress Update on RHB104 Phase III Crohn's Disease Program and Introduces Option for Early Stop for Success in Q22017 An option for early stop for success for overwhe...
View ArticleRedHill Biopharma Ltd. RedHill Biopharma to Host Webcast Today at 830 am EDT...
TELAVIV Israel 20161006 1305 CEST GLOBE NEWSWIRE RedHill Biopharma Ltd. NASDAQRDHL TASERDHL "RedHill" or the "Company" a biopharmaceutical company primarily focused on developme...
View ArticleRedHill Biopharma Ltd. RedHill Biopharma to Host Webcast Today at 830 am EDT...
RedHill Biopharma to Host Webcast Today at 830 am EDT Following Announcement of Progress Update on RHB104 Phase III Crohn's Disease Program Including the Introduction of an Option for Early Stop...
View ArticleRedHill Biopharma Provides Progress Update on RHB104 Phase III Crohns Disease...
An option for early stop for success for overwhelming efficacy has been introduced into the ongoing first Phase III study with RHB104 for Crohns disease the MAP US study and analysis is expected in the...
View ArticleRedHill Biopharma to Host Webcast Today at 830 am EDT Following Announcement...
TELAVIV Israel October 6 2016 B3C newswire RedHill Biopharma Ltd. NASDAQ RDHL TASE RDHL RedHill or the Company a biopharmaceutical company primarily focused on development and commercialization of late...
View ArticleRedHill Biopharma Provides Progress Update on RHB104 Phase III Crohn's...
RedHill Biopharma Provides Progress Update on RHB104 Phase III Crohn's Disease Program and Introduces Option for Early Stop for Success in Q22017 An option for early stop for success for...
View ArticleRedHill Biopharma to Host Webcast Today at 830 am EDT Following Announcement...
RedHill Biopharma to Host Webcast Today at 830 am EDT Following Announcement of Progress Update on RHB104 Phase III Crohn's Disease Program Including the Introduction of an Option for Early...
View ArticlePenn VetCHOP partnership probes link between cattle and Crohn's disease
Researchers still have a lot to learn about Crohn's disease a chronic form of inflammatory bowel disorder that affects as many as 700000 Americans. It's unknown for example precisely how heredity...
View ArticleResearchers to investigate similarities between Crohn's and Johne's disease...
Researchers still have a lot to learn about Crohn's disease a chronic form of inflammatory bowel disorder that affects as many as 700000 Americans.
View ArticleSoligenix Announces ReverseSplit in Preparation for Proposed UpListing of its...
PRINCETON N.J. Oct. 7 2016 PRNewswire Soligenix Inc. OTCQB SNGXD Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases...
View ArticleRedHill adds option for Phase 3 early stop in Crohn's
The biotech is confident an interim analysis next year in its Phase 3 trial will show positive results.
View ArticleCommon foodpoisoning bacteria linked to increased risk of Crohn's disease
People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life according to a new study led by researchers...
View ArticleFoodpoisoning bacteria may be behind Crohn's disease
People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life according to a new study.
View ArticleZeria Pharmaceutical receives approval in Japan for Zentacort capsules
Pharmaceutical companyÂZeriaÂhas receivedÂapproval from the Japanese Ministry of Health Labour and Welfare MHLWÂfor its Zentacort 3mg capsules which will used to treatÂCrohn's Disease CD.
View ArticleInternationally Renowned Colorectal Surgeon Named Director of Inflammatory...
NEW YORK Oct. 11 2016 PRNewswireUSNewswire Feza Remzi MD a world renowned colorectal surgeon and pioneer in the surgical management of inflammatory bowel disease IBD and other complex colorectal...
View ArticleArena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod...
SAN DIEGO Oct. 11 2016 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA today announced that Dr. Laurent PeyrinBiroulet will present etrasimod S1P receptor profile data at the United European...
View Article